doi.org

Alzheimer Disease in 2020

  • ️Thu Nov 01 2012
  1. Eckhard Mandelkow2 and
  2. Dennis J. Selkoe3
  1. 1Department of Neurology, Alzheimer’s Disease Research Center, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri 63110
  2. 2Max-Planck Unit for Structural Molecular Biology, c/o DESY, 22607 Hamburg, Germany; and DZNE, German Center for Neurodegenerative Diseases, and CAESAR Research Center, 53175 Bonn, Germany
  3. 3Center for Neurologic Diseases, Harvard Medical School and Brigham and Women’s Hospital, Boston, Massachusetts 02115
  1. Correspondence: holtzman{at}neuro.wustl.edu

Abstract

Remarkable advances in unraveling the biological underpinnings of Alzheimer disease (AD) have occurred during the last 25 years. Despite this, we have made only the smallest of dents in the development of truly disease-modifying treatments. What will change over the next 10 years? While the answer is not clear, we make several predictions on the state of the field in 2020, based on the rich knowledge described in the other contributions in this collection. As such, our predictions represent some of the principal unresolved questions that we believe deserve special investigative attention in the coming decade.

  • Copyright © 2012 Cold Spring Harbor Laboratory Press; all rights reserved

Richard Sever interviews Joan Brugge